Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria

Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria

Heart failure (HF) is one of the main causes of morbidity, mortality, and high healthcare costs. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced cardiovascular mortality and hospitalization for HF compared to placebo in patients with chronic HF, and reduced ejection fracti...

Full description

Bibliographic Details
Main Authors: Anna Camps-Vilaró, Juan F. Delgado-Jiménez, Núria Farré, Helena Tizón-Marcos, Jesús Álvarez-García, Juan Cinca, Irene R. Dégano, Jaume Marrugat
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Journal of Clinical Medicine
Subjects:
heart failure
reduced ejection fraction
cardiovascular disease
cardiovascular therapy
dapagliflozin
sodium-glucose cotransporter-2 inhibitor
Online Access:https://www.mdpi.com/2077-0383/9/7/2089

Internet

https://www.mdpi.com/2077-0383/9/7/2089

Similar Items